Skip to main content
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. — Investor Relations & Filings

Ticker · VVOS ISIN · US92859E1082 US Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2023-09-06 Proxy Solicitation & In…
Country US United States of America
Listing US VVOS

About Vivos Therapeutics, Inc.

https://vivos.com/

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company's core offering is The Vivos System, a non-surgical treatment that uses proprietary oral appliances. These devices are designed to address underlying dentofacial abnormalities that can restrict the airway. The treatment protocol aims to promote the natural growth and development of the jaw and airway in both adult and pediatric patients. Vivos provides its technology and training to a network of licensed dentists and medical professionals who deliver the therapy.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2023
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to the Securities Exchange Act of 1934. It is titled 'Supplemental Proxy Materials For the Annual Meeting of Stockholders on September 22, 2023' and includes detailed information about proposals to be voted on at the annual meeting, such as a reverse stock split, increase in stock option plan shares, election of directors, and ratification of auditors. The document is clearly proxy solicitation material, intended to inform and solicit votes from shareholders for the upcoming annual meeting. It is not the annual report itself, nor an earnings release or other financial report. The presence of detailed voting proposals and encouragement to vote 'FOR' aligns with the definition of Proxy Solicitation & Information Statement (PSI). Therefore, the correct classification is PSI with high confidence.
2023-09-06 English
Proxy Solicitation & Information Statement 2023
Proxy Solicitation & Information Statement
2023-08-28 English
Delisting Announcement 2023
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. The key content is an Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. It details that the company did not meet Nasdaq's minimum stockholders' equity requirement and discusses the process and timeline for regaining compliance or potential delisting. The document is not a full financial report but an official announcement regarding the company's listing status. Therefore, it fits the definition of a Delisting Announcement (DLST). The document length is about 4905 characters, which is sufficient for a substantive announcement rather than a brief notice or certification. Hence, the classification is DLST with high confidence.
2023-08-21 English
Proxy Solicitation & Information Statement 2023
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically identified as a Preliminary Proxy Statement for the 2023 Annual Meeting of Stockholders of Vivos Therapeutics, Inc. It includes detailed information about the meeting agenda, voting procedures, director elections, stock option plan amendments, and other shareholder matters. The document is not a report of voting results, nor is it an announcement of a report publication. It is not a financial report or earnings release. The content and form clearly match the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2023-08-16 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Vivos Therapeutics, Inc. It announces the issuance of a press release with financial results for the second quarter ended June 30, 2023. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the document itself does not contain detailed financial statements or substantive financial data. The document length is 3964 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 8-K filings announcing events or press releases without full financial data.
2023-08-16 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-08-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.